Through our commitment to drug discovery and development, Astellas has a rich and unique pipeline that is continually evolving.
Selectivity and focus
From the hundreds of different drug candidates and new technologies under our investigation, we identify and strictly prioritise those with greatest potential to deliver new standards of care – critical for our commitment to produce first-in-class and best-in-class therapies.
We aim to develop drugs that accurately target biological processes in patients with specific disease profiles, with companion diagnostics to identify those people who will receive most benefit.
At Astellas, R&D isn’t just about us. We proactively utilise external resources and specialist excellence at every stage of the R&D process – enabling us to deliver as many innovative new drugs as possible. In the drug discovery phase, we have collaborations with academic research institutions including Kyoto University and RIKEN. In the development phase, we partner with multiple organisations to harness complementary capabilities.
Through our commitment to drug discovery and development, Astellas has a rich and unique pipeline that is continually evolving. Recent work has focused on 23 investigational programmes in Phase III/registration and 15 in Phase II.